Search Results

. Following frontline TC, the benefit of subsequent chemotherapy is modest, with a median PFS of 3 to 4 months and OS of 6 to 12 months. 1 The anti-VEGF antibody bevacizumab is also active in advanced EC as monotherapy and has been explored in combination

metastatic colon cancer. The Use of Biologic Agents in the Older Population Bevacizumab The addition of the vascular endothelial growth factor antibody bevacizumab has been shown to improve progression-free and overall survivals among patients

metastatic colorectal cancer treated with cetuximab . Ann Oncol 2008 ; 19 : 508 – 515 . 28 Punt CJ Tol J Rodenburg CJ . Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal

] +/- panitumumab in first-line treatment of mCRC) suggests that the presence of these additional RAS mutations predict for lack of benefit. Data from the large phase II randomized study PEAK (FOLFOX plus panitumumab vs FOLFOX plus bevacizumab in first

. The safety of bevacizumab . Expert Opin Drug Saf 2006 ; 5 : 289 – 301 . 13. Jain RK . Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy . Nat Med 2001 ; 7 : 987 – 989 . 14

, bevacizumab is the same price per milligram for patients with metastatic colorectal cancer (5 mg/kg every 2 weeks), in whom it provides a median overall survival benefit of 4.7 months 16 (hazard ratio [HR] for death, 0.66; 95% CI, 0.54-0.81; P < .001), as

approval, MSKCC staff called the decision a “no brainer.” The median survival benefit with the drug was minimal (1.4 months); the drug has a similar mechanism of action to bevacizumab, which is already available for advanced colorectal cancer; and the drug

,” commented Dr. Borad. Immunotherapy The combination of antiangiogenics with immune checkpoint inhibitors (atezolizumab + bevacizumab) is a recommended option for certain patients. “We know that hepatocellular cancers have a tumor microenvironment in a

According to Dr. Haddad, other research looking at targets besides immunotherapy has been “disappointing.” A long-running phase III trial of chemotherapy with or without bevacizumab in patients with recurrent/metastatic HNSCC showed no statistically

/print certificate. Release date: November 4, 2014; Expiration date: November 4, 2015 Learning Objectives Upon completion of this activity, participants will be able to: Describe the challenges of MRI assessment in patients receiving bevacizumab